Labels
Posted by

Novo Nordisk vs. Eli Lilly — The GLP‑1 Market Showdown (2026 Perspective)

Last Updated: September 2026 | Reviewed by the One Day Advisor Editorial Team

Quick Answer

Eli Lilly is currently winning the GLP-1 market on nearly every financial metric: Q2 2026 revenue of $22.97 billion (+48% year-over-year) versus Novo Nordisk's roughly $5.15 billion in adjusted operating profit on flat-to-declining sales, and a market capitalization of roughly $1.0–1.1 trillion versus Novo's ~$206 billion — a gap of about 5-to-1 that didn't exist two years ago. Lilly's edge is built on tirzepatide's efficacy advantage, the April 2026 launch of Foundayo (the first oral GLP-1 pill with no food/water restrictions), and a completed Phase 3 package for retatrutide (up to 28.7% weight loss). Novo Nordisk is fighting back with a fast-launching Wegovy pill (5 million U.S. prescriptions in 30 weeks) and CagriSema, an amylin/GLP-1 combination now under FDA review with a decision expected by late 2026 — but a disappointing head-to-head trial against tirzepatide and a 9,000-job restructuring under new CEO Mike Doustdar show the company still playing catch-up.

The fight for dominance in GLP-1 medicines — drugs originally built for diabetes that have become the biggest growth story in pharmaceutical history — has entered a new phase. Two years ago, Novo Nordisk and Eli Lilly were running roughly neck-and-neck. As of this September 2026 update, that is no longer true. Lilly's Q2 2026 revenue grew 48% to $22.97 billion, its market cap has crossed the $1 trillion mark, and it now has an approved oral GLP-1 pill (Foundayo) on the market. Novo Nordisk, meanwhile, is mid-restructuring under a new CEO, still waiting on an FDA verdict for its next-generation drug CagriSema, and trading at roughly a fifth of Lilly's valuation. Here is what changed, what the numbers say now, and what it means for anyone following the two companies as investors, patients, or both.

Eli Lilly vs. Novo Nordisk in the GLP-1 Market

1. September 2026 Headlines: What's Different Since Last Update

  • Foundayo is on the market. The FDA approved Eli Lilly's orforglipron — branded Foundayo — on April 1, 2026, for adults with obesity or overweight with a weight-related condition. It is the first GLP-1 pill that can be taken at any time of day without food or water restrictions, and it launched under the FDA's National Priority Voucher Program with an unusually fast review. In the pivotal ATTAIN-1 trial, patients on the highest dose lost an average of 27.3 lb (12.4%) versus 2.2 lb (0.9%) on placebo — meaningful, but still short of injectable tirzepatide's efficacy.
  • CagriSema is still waiting on the FDA. Novo Nordisk filed its New Drug Application for CagriSema (cagrilintide plus semaglutide) in December 2025, and a decision is expected by late 2026. In February 2026, a head-to-head Phase 3 readout against tirzepatide came in weaker than hoped, triggering a sharp share-price drop. CagriSema is not yet approved anywhere in the world as of this update.
  • Tirzepatide's cardiovascular case is now proven, not pending. The SURPASS-CVOT trial reported topline results in mid-2025 and was published in full afterward: tirzepatide was non-inferior to dulaglutide on major adverse cardiovascular events (8% lower relative risk) and cut all-cause mortality by 16%. A post-hoc analysis presented at the American College of Cardiology's 2026 meeting added further kidney- and heart-protection detail. This closes a gap the original comparison flagged as "expected."
  • Novo's oral Wegovy pill is a genuine bright spot. Since its U.S. launch, the Wegovy pill has passed 5 million cumulative prescriptions in roughly 30 weeks and captured about 90% of the U.S. oral obesity-pill market — the one number in Novo's recent results that has clearly outperformed expectations.
  • Washington reset GLP-1 pricing for everyone. Under "most favored nation" deals struck with the Trump administration in November 2025 and rolled out through 2026 via the TrumpRx platform, both companies cut U.S. list prices sharply and Medicare began covering obesity indications for the first time. See Section 7 for the specifics — this is arguably the single biggest structural change to the GLP-1 business model since the drugs were approved.
  • Novo is still absorbing its 2025 restructuring. New CEO Maziar Mike Doustdar, who replaced the ousted Lars Fruergaard Jørgensen in mid-2025, cut roughly 9,000 jobs (about 11% of the workforce) to save an estimated $1.3 billion a year by the end of 2026. A mandatory five-day return-to-office policy and a Q2 2026 write-down tied to the discontinued obesity candidate monlunabant show the cost-cutting is ongoing.

2. Company & Drug Overview

  Eli Lilly Novo Nordisk
Flagship injectable Tirzepatide (Mounjaro for diabetes, Zepbound for obesity) — dual GLP-1/GIP agonist Semaglutide (Ozempic for diabetes, Wegovy for obesity) — GLP-1 only
Flagship oral pill Foundayo (orforglipron) — approved April 2026, obesity indication; diabetes filing planned later in 2026 Rybelsus (oral semaglutide, diabetes) and the Wegovy pill (oral semaglutide, obesity) — both on the market
Next-gen candidate Retatrutide — GIP/GLP-1/glucagon triple agonist; Phase 3 complete, BLA planned Q1 2027 CagriSema — cagrilintide (amylin) + semaglutide; FDA decision expected late 2026
Other 2026 approvals Tirzepatide added cardiovascular outcomes data (SURPASS-CVOT) Awiqli — first once-weekly basal insulin, approved March 2026, US launch H2 2026
CEO David Ricks Maziar Mike Doustdar (since August 2025)

3. Efficacy & Clinical Data

Head-to-head, tirzepatide's efficacy edge over semaglutide that defined the 2024–2025 narrative still holds, and the newest data only widens Lilly's lead on the horizon with retatrutide. Evidence levels below follow the CEBM hierarchy (1a/1b = randomized controlled trial or meta-analysis of RCTs; 2b/3b = single cohort or non-randomized comparative study).

Measure Tirzepatide (Lilly) Semaglutide (Novo) Evidence tier
Weight loss, obesity without T2D (highest approved dose) 20.2–20.9% 13.7–14.9% 1b (head-to-head RCT, SURMOUNT-5)
A1C reduction, type 2 diabetes –2.0 to –2.3% –1.5 to –1.9% 1b
Cardiovascular outcome trial result Non-inferior to dulaglutide; 8% lower MACE-3, 16% lower all-cause mortality (SURPASS-CVOT, published 2025–2026) Superior to placebo on MACE (SELECT trial, approved label since 2024) 1b
Heart-attack risk, real-world comparison Baseline comparator Observational data suggested a relative reduction versus tirzepatide (2025 real-world analysis) 3b (retrospective cohort — not a randomized head-to-head; interpret cautiously)
Gastrointestinal tolerability Nausea 25–44%, vomiting 10–18%; generally comparable at top doses Similar range 1b

Where retatrutide and CagriSema fit in: neither is approved yet, so treat the numbers below as pipeline data rather than current standard of care.

  • Retatrutide (Lilly, Phase 3 complete, evidence tier 1b): Across the TRIUMPH program, the 12 mg dose delivered 28.3% weight loss at 80 weeks in general obesity (TRIUMPH-1), extending to 30.3% at 104 weeks in a smaller continuation cohort; 28.7% weight loss plus a 75.8% reduction in WOMAC knee-pain scores in patients with obesity and knee osteoarthritis (TRIUMPH-4); 20.8% weight loss in patients with type 2 diabetes (TRIUMPH-2); and 22.6% weight loss plus meaningful drops in triglycerides and blood pressure in patients with established cardiovascular disease (TRIUMPH-3). A dedicated head-to-head trial against tirzepatide (TRIUMPH-5) is active but not yet reported.
  • CagriSema (Novo, under FDA review, evidence tier 1b for trial data / pending for regulatory outcome): The REDEFINE program showed strong efficacy on its own terms — roughly 20%+ weight loss in the general obesity population and 15.7% weight loss with a 1.8-point A1C reduction in patients with type 2 diabetes over 68 weeks. The complication is comparative, not absolute: a 2026 head-to-head trial against tirzepatide fell short of expectations, reinforcing that CagriSema's role may end up being a strong option rather than a category leader.

4. Q2 2026 Earnings — What Investors Need to Know

Metric (Q2 2026) Eli Lilly Novo Nordisk
Revenue $22.97 billion (+48% YoY) DKK 78.5 billion (~+3% at constant exchange rates, reported)
Key obesity/diabetes brands Mounjaro $9.94B (+91%); Zepbound $4.93B (+46%) — combined ~65% of revenue Wegovy pill drove the beat; injectable Wegovy and Ozempic both under pricing pressure
Profitability Non-GAAP EPS $8.38 (+33%); reported EPS $7.94 (+26%) Adjusted operating profit DKK 33.4B (~$5.15B, +11% CER); net profit DKK 21.0B
Full-year 2026 guidance Raised to $85–87 billion revenue (from a prior $82–84B range) Improved to 0% to –6% adjusted sales/operating-profit growth at constant exchange rates (from a prior –4% to –12% range)
Market reaction Shares rose roughly 4% on the beat-and-raise Shares fell roughly 5% despite the guidance raise, on continued concern over pricing and the quality of the beat

Read plainly: Lilly is still growing off a much larger and faster-growing obesity/diabetes base, while Novo's "beat" was really a smaller-than-feared decline. Novo's own full-year outlook — a range that still spans "flat" to "down 6%" — tells the more honest story about where the company stands competitively right now.

5. Stock & Valuation Snapshot (Early September 2026)

Metric Eli Lilly (LLY) Novo Nordisk (NVO)
Share price ~$1,150–1,160 ~$46–47
Market capitalization ~$1.0–1.1 trillion ~$205–210 billion
52-week range $712.05 – $1,292.65 $35.12 – $64.16
P/E (trailing) ~39x ~11.5x
Forward P/E ~28x ~15x
Dividend yield ~0.6% ~3–4%

The valuation gap has flipped from the framing investors used through 2024–2025. Lilly's market cap is now roughly five times Novo's — up from a much narrower gap two years ago — while Novo trades at a P/E discount that some value-oriented analysts see as reflecting the market's skepticism about Novo's near-term growth rather than a bargain. Neither the premium on Lilly nor the discount on Novo is a guarantee of future returns in either direction; both reflect genuine, different sets of risks.

6. Pipeline & 2026–2027 Launches

Eli Lilly

  • Foundayo (orforglipron): Approved for obesity/overweight (April 2026); a type 2 diabetes indication is expected to be submitted later in 2026, supported by positive Phase 3 data already reported.
  • Retatrutide: Full Phase 3 package (TRIUMPH-1 through TRIUMPH-4) complete across general obesity, knee osteoarthritis, type 2 diabetes, and cardiovascular disease populations. A Biologics License Application covering obesity, obstructive sleep apnea, and knee osteoarthritis pain is planned for Q1 2027. A head-to-head trial against tirzepatide (TRIUMPH-5) is still running.
  • Business development: Lilly has been acquisitive through 2026, completing deals for Orna Therapeutics, Centessa Pharmaceuticals, Kelonia Therapeutics, and Ajax Therapeutics, plus an agreement to acquire Merida Biosciences — broadening its pipeline beyond metabolic disease into RNA and cell-therapy platforms.

Novo Nordisk

  • CagriSema: NDA under FDA review; decision expected by late 2026. A type 2 diabetes indication would follow separately if approved.
  • Oral Wegovy pill: Already launched and outperforming internal expectations on prescription volume, though at lower per-prescription pricing than injectables.
  • Awiqli: The first FDA-approved once-weekly basal insulin, approved March 2026, with a full U.S. launch planned for the second half of 2026 — a diversification move outside the GLP-1 category.
  • Pipeline setback: Novo took a roughly DKK 4.0 billion non-cash write-down in Q2 2026 tied to monlunabant, an oral CB1-antagonist obesity candidate that did not pan out — a reminder that Novo's "beyond GLP-1" bets carry real execution risk.

7. TrumpRx and the New GLP-1 Pricing Reality

In November 2025, both companies struck "most favored nation" pricing agreements with the Trump administration, which took effect through 2026 via the new TrumpRx.gov platform. The headline terms:

  • Medicare and Medicaid now pay roughly $245/month for GLP-1 drugs across diabetes and obesity uses (down from list prices that ran $1,000–$1,350/month), with a Medicare patient copay around $50/month for covered uses.
  • Direct-to-consumer prices on TrumpRx started around $350/month, with a stated glide path down to about $245/month over roughly 24 months.
  • Both companies committed to launching future oral GLP-1 pills — including Foundayo and the Wegovy pill — at a starting-dose price around $145–150/month through Medicare, Medicaid, and TrumpRx.
  • In exchange, both companies received a three-year tariff exemption and a commitment to extend MFN-style pricing to future drug launches.
  • A wrinkle confirmed only in mid-2026: the $245 Medicare/Medicaid price for obesity uses is contingent on private Medicare insurers agreeing to cover GLP-1s for all indications at the $50 copay — a condition that was not prominently disclosed when the deal was first announced, and one that could affect how quickly the lower pricing actually reaches obesity patients on Medicare.

For investors, the net effect cuts both ways: lower per-prescription pricing pressures margins, but dramatically expanded Medicare/Medicaid coverage for obesity — for the first time — is a genuine volume catalyst that neither company had in its 2024 base case.

8. Emerging GLP-1 & Related Stocks to Watch

The list of credible challengers has shifted meaningfully since the last update — one major name has effectively exited, while others have advanced.

  • Pfizer (PFE) — largely out of the oral GLP-1 race. Pfizer discontinued danuglipron, its oral GLP-1 candidate, in April 2025 after a liver-safety signal in clinical testing. The company's metabolic pipeline now centers on an earlier-stage oral GIPR-antagonist candidate, meaning Pfizer is no longer a near-term threat to Lilly or Novo in oral GLP-1s.
  • Amgen (AMGN) — MariTide, still in Phase 3. Amgen's once-monthly antibody-peptide candidate showed roughly 20% weight loss (obesity) and 17% weight loss (obesity plus type 2 diabetes) at 52 weeks in Phase 2. The Phase 3 MARITIME program spans nine global trials in obesity, obstructive sleep apnea, cardiovascular disease, and heart failure, with three type 2 diabetes trials starting in 2026. Key readouts are still pending as of this update; Amgen has narrowed its broader obesity pipeline to focus resources on MariTide.
  • Zealand Pharma (Nasdaq: ZEAL) with Roche — petrelintide, an amylin-only approach. Phase 2 data (ZUPREME-1) showed 10.7% mean weight loss at 42 weeks with tolerability described as close to placebo — a potential differentiator if it holds up in Phase 3, which Zealand and Roche plan to start in the second half of 2026. A combination trial pairing petrelintide with Roche's GLP-1/GIP agonist enicepatide is also planned for late 2026.
  • Altimmune (ALT) — pemvidutide, increasingly liver-disease focused. After a mixed Phase 2b readout in MASH (fatty liver disease) in mid-2025, Altimmune raised substantial new capital in April 2026 to keep pemvidutide moving across obesity, MASH, and alcohol-associated liver disease — a narrower, more diversified bet than a head-on obesity challenge to Lilly and Novo.
  • Sanofi, AstraZeneca, and Chinese biotech licensors. Both companies continue to build out metabolic-disease and cardiometabolic programs, and 2026 has also seen a wave of Western pharma companies licensing early-stage GLP-1 and amylin assets from Chinese biotechs — a trend worth watching for anyone tracking where the next wave of competition could come from.

9. Investment & Strategic Implications

Lilly's case: broader product line (injectable and oral, diabetes and obesity), a completed retatrutide Phase 3 package that could extend its efficacy lead into 2027, and financial results that keep beating already-high expectations. The risk is priced-in expectations — at roughly 39x trailing earnings, a lot of future growth is already reflected in the stock.

Novo's case: a fast-launching oral pill, a still-massive global GLP-1 installed base, a dividend yield several times Lilly's, and a valuation that already reflects meaningful pessimism. The risk is execution — the CagriSema head-to-head miss, the ongoing restructuring, and a full-year guidance range that still includes the possibility of a down year.

Emerging players: Amgen's MariTide and the Zealand/Roche amylin approach are the two developments most likely to reshape the competitive picture over the next 12–18 months if their Phase 3 data read out well; Pfizer's exit is a reminder that oral small-molecule GLP-1 development is harder than it looks.

None of this is a recommendation to buy or sell either stock. This is factual information for your own research — see the disclaimer below.

10. Using This Guide with Claude, ChatGPT, Gemini, or Perplexity

If you're pulling this data into an AI assistant to build your own comparison or portfolio note, a few tips get better results:

  • Ask for the delta, not just the numbers. Prompt with "compare Lilly's and Novo's Q2 2026 guidance changes and explain what each implies for the rest of 2026" rather than just "give me the revenue figures" — the reasoning is usually more useful than the raw data alone.
  • Specify a date. GLP-1 news moves fast; ask your assistant to note the "as of" date for any stock price, guidance figure, or regulatory status it gives you, and to flag if it's relying on training data versus a live search.
  • Separate approved facts from pipeline data. When asking about retatrutide or CagriSema, explicitly ask the assistant to distinguish "FDA-approved" from "Phase 3 topline" from "under review" — this is the single most common source of confusion in AI-generated pharma summaries.
  • Cross-check pricing claims. TrumpRx pricing terms have already been clarified and adjusted once since the initial November 2025 announcement; ask for the most recent confirmation rather than the original press release framing.

Conclusion

Eli Lilly is not just ahead of Novo Nordisk in the GLP-1 race — as of September 2026, the gap has widened into a different weight class entirely, with Lilly's market capitalization now roughly five times Novo's. Foundayo's launch, a completed retatrutide Phase 3 package, and a resolved (and favorable) cardiovascular outcomes trial for tirzepatide have reinforced Lilly's lead on nearly every axis that matters to investors. Novo Nordisk remains a real company with real assets — a fast-selling oral pill, global distribution, and a much cheaper valuation — but it is running a recovery story under a new CEO, not a leadership story. CagriSema's FDA decision, expected by the end of 2026, is the single most important near-term catalyst that could either narrow the gap or confirm it.

Frequently Asked Questions

Is Eli Lilly bigger than Novo Nordisk now?

Yes, by a wide margin. As of early September 2026, Eli Lilly's market capitalization is roughly $1.0–1.1 trillion versus Novo Nordisk's roughly $205–210 billion — about a 5-to-1 gap that has widened significantly over the past two years as Lilly's tirzepatide-driven growth has outpaced Novo's semaglutide franchise.

Is CagriSema approved by the FDA?

No. Novo Nordisk filed for FDA approval of CagriSema in December 2025, and a decision is expected by late 2026. It is not approved or available anywhere in the world as of this update.

What is Foundayo and how is it different from Ozempic or Wegovy?

Foundayo (orforglipron) is Eli Lilly's oral GLP-1 pill, approved by the FDA in April 2026 for obesity and overweight with a weight-related condition. Unlike Novo Nordisk's oral semaglutide products (Rybelsus and the Wegovy pill), Foundayo can be taken at any time of day without restrictions on food or water intake, which Lilly has positioned as a meaningful convenience advantage.

Will GLP-1 drugs get cheaper in the U.S.?

For many patients, yes. Under pricing agreements both companies struck with the U.S. government, Medicare and Medicaid now pay roughly $245/month for GLP-1 drugs (down from prior list prices of $1,000–$1,350/month), with some Medicare patients paying a $50/month copay. Direct-to-consumer prices through the TrumpRx platform started around $350/month with a planned decline toward $245/month over about two years. Actual out-of-pocket costs still vary by insurance plan, dose, and indication.

Which is more effective for weight loss, tirzepatide or semaglutide?

In head-to-head trial data, tirzepatide (Mounjaro/Zepbound) has consistently produced greater average weight loss than semaglutide (Ozempic/Wegovy) — roughly 20–21% versus roughly 14–15% at the highest approved doses. This is trial-level average data; individual results vary, and the choice of medication should be made with a physician based on a patient's full medical history.

Is retatrutide approved yet?

No, retatrutide (Eli Lilly's triple-hormone agonist) is not yet FDA-approved. Its Phase 3 program is complete, with results showing weight loss up to 28.7% in some trial populations, and Lilly plans to submit a Biologics License Application to the FDA in the first quarter of 2027.

Related Reading on One Day Advisor

References

  1. Eli Lilly and Company — Q1 and Q2 2026 earnings releases and SEC filings (investor.lilly.com, sec.gov)
  2. Novo Nordisk A/S — Q1 and Q2 2026 financial reports and 6-K filings (novonordisk.com, sec.gov)
  3. U.S. FDA — Foundayo (orforglipron) approval announcement, April 1, 2026
  4. Novo Nordisk — CagriSema NDA filing announcement, December 18, 2025, and subsequent regulatory updates
  5. Eli Lilly — SURPASS-CVOT topline and published results; American College of Cardiology 2026 post-hoc presentation
  6. Eli Lilly — TRIUMPH-1 through TRIUMPH-4 retatrutide Phase 3 topline results, December 2025–July 2026
  7. The White House / CMS — Most Favored Nation GLP-1 pricing framework, November 2025; TrumpRx implementation updates through mid-2026
  8. Zealand Pharma / Roche — ZUPREME-1 Phase 2 and Phase 3 initiation announcements, 2026
  9. Amgen — MariTide Phase 2 results and MARITIME Phase 3 program updates
  10. Pfizer — Danuglipron program discontinuation announcement, April 2025
  11. Stock and market-cap data: StockAnalysis.com, Yahoo Finance, MarketBeat, CNBC, CNN Markets — as of September 3–4, 2026

Editor's Note

This is a full rebuild of our November 2025 comparison, updated for Q2 2026 earnings from both companies, Foundayo's April 2026 approval and launch, the December 2025 CagriSema NDA filing and its February 2026 head-to-head trial setback, the completed retatrutide Phase 3 package, the now-published SURPASS-CVOT cardiovascular results, Novo Nordisk's leadership transition and restructuring, and the TrumpRx/Most Favored Nation pricing framework that took effect through 2026. All stock prices, market capitalizations, and financial figures reflect data available as of the September 3–4, 2026 close and are subject to change.

Disclaimer

This article is for educational and informational purposes only and does not constitute personalized financial, investment, or medical advice. One Day Advisor is not a registered investment advisor, broker-dealer, or financial planner, and this content should not be the sole basis for any investment decision. Stock prices, market capitalizations, revenue figures, and clinical trial data are based on publicly available sources as of the dates noted above and can change quickly, particularly around earnings releases and FDA decisions. Past performance is not a guarantee of future results. Always conduct independent research and consult a qualified, licensed financial advisor before making investment decisions, and consult a physician before starting, stopping, or changing any medication, including GLP-1 therapies.


Labels:

Comments

Post a Comment

Popular Posts